3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
10
Withdrawn
4
No longer available
2
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Cyclophosphamide
30
Rituximab
23
zanubrutinib
18
fludarabine
14
Vincristine
14
venetoclax
13
Prednisone
13
blinatumomab
12
Magnetic Resonance Spectroscopy
12
Specimen Handling
11
Doxorubicin
11
obinutuzumab
10
Bendamustine Hydrochloride
10
Lenalidomide
9
Dexamethasone
8
polatuzumab vedotin
7
glofitamab
7
Methotrexate
7
Radiotherapy
6
Prednisolone
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Cytarabine
6
Biopsy
6
pirtobrutinib
5
pegaspargase
5
Immunotherapy, Adoptive
5
tislelizumab
4
tafasitamab
4
selinexor
4
orelabrutinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
navitoclax
×
Lymphoid
×
Clear all
NCT05054465
2021-09-23
ITALLI001
Israeli Medical Association
Phase 1/2
Not yet recruiting
48 enrolled